NASDAQ · Health care

Aspire Biopharma Holdings, Inc. (ASBP)

It posted a net loss of $11M. At June 30, 2026 it held $12.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Price

$8.32

-4.37% on the day · September 25, 2026

52-week range $0.11 to $18.76

Market cap

$11.7M

What Aspire Biopharma Holdings, Inc. does

Aspire Biopharma Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ASBP.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$6.2K	-$19.4M	-$24.5M	-$16.38	n/a
2024	n/a	-$1.2M	-$1.3M	-$1.90	n/a
2023	n/a	n/a	$4.5M	n/a	n/a
2022	n/a	n/a	$3.3M	n/a	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around October 20, 2026.

Estimated from its filing rhythm: about 68 days after its last report of August 13, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where ASBP ranks in Health care

Revenue$6.2K

#643 of 646 in Health care · Bottom 1%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Aspire Biopharma Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 9, 2026
Bylaws or fiscal year changed 8-K
September 8, 2026
Investor disclosure 8-K
August 19, 2026
Investor disclosure 8-K
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 13, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue was $63.1K; diluted EPS -$1.22 versus -$48.19.
August 10, 2026
Passive stake (5% or more) SCHEDULE 13G
August 10, 2026
Material agreement 8-K
August 6, 2026
Passive stake changed SCHEDULE 13G/A
July 20, 2026
Other event 8-K
July 2, 2026
Passive stake (5% or more) SCHEDULE 13G

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 10, 2025. Insider transactions on SEC

Who owns ASBP

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Lance Friedman13G, passive	7.92%	107,323	August 6, 2026
Gary Shirinyan13G, passive	7.7%	99,900	August 10, 2026
Rubenbauer Alois Ryan III13G, passive	5%	65,000	July 2, 2026

Latest filings below 5%: Highbridge Capital Management, LLC 0% (August 14, 2026); Ardsley Advisory Partners LP 0% (May 13, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ASBP

What does Aspire Biopharma Holdings, Inc. do?

Aspire Biopharma Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ASBP.

Is Aspire Biopharma Holdings, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $11M.

When did Aspire Biopharma Holdings, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the bylaws or fiscal year changed from September 9, 2026.

Similar companies

Compare ASBP with

Compare ASBP with any company

Follow ASBP

Get an email when Aspire Biopharma Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ASBP: get an email when it files

Where the numbers come from

Financial figures are the values Aspire Biopharma Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.